XRCC6 and prostate carcinoma: In this study, the authors demonstrated that the prostate cancer cells pretreated with the HDACi, trichostatin A, suberoylanilide hyroxamic acid, MS-275, and OSU-HDAC42, resulted in an increase in Ku70 acetylation which was followed by a lower DNA-binding affinity without the disruption of the Ku70/80 complex.